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Introduction 
Acute myeloid leukemia (AML) is an aggressive hematologic malignancy associ-
ated with poor outcomes.  Current standard treatment includes remission induction
chemotherapy, typically consisting of cytarabine combined with an anthracycline,
an approach which has remained unchanged for more than 30 years.1-3  Over the last
decade, a series of novel therapeutics have been combined with this chemotherapy
backbone, with most yielding negative or inconsistent results.4-7 More recently,
some improvement in outcomes have been noted with certain FLT3 tyrosine kinase
inhibitors and antibody-drug conjugates8-10 in combination with induction
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ABSTRACT
chemotherapy; such benefits may be limited to certain
subcategories of AML. For the majority of patients, new
and effective approaches are still needed to enhance the
current standard of care.
Aurora kinases are a family of serine-threonine kinases
that regulate multiple phases of the mitotic signaling cas-
cade.11 Aberrant upregulation of aurora A kinase (AAK) has
been demonstrated in multiple malignancies, and its inhi-
bition suppresses proliferation of neoplastic cells11,12 by
triggering mitotic errors, aneuploidy, senescence, and
apoptosis.13,14 This process appears especially applicable to
cells during or shortly following exposure to cytotoxic
chemotherapy.15-18 
Alisertib is a potent, orally available inhibitor of AAK.
Preclinical studies in AML cell lines, patient samples, and
animal models have demonstrated potent cytotoxicity,
diminished clonal survival, and promotion of apoptosis.15
Alisertib has been evaluated for safety and efficacy in mul-
tiple clinical studies,19-22 including those regarding hemato-
logical malignancy,23-26 and has been associated with clini-
cal response. Alisertib has also been studied in combina-
tion with other neoplastic agents, where it was also
demonstrated to be safe and well-tolerated.15-18
There has been growing interest in targeting AAK as a
therapeutic approach in myeloid neoplasms, and pre-clin-
ical studies have suggested that targeting AAK expression
with alisertib promotes tumor sensitivity to cytarabine.15
A subsequent phase II trial of alisertib monotherapy
demonstrated efficacy in a subset of patients with AML
and high-grade myelodysplastic syndromes (MDS).27
Given the oncogenic role of aurora kinases, the activity of
alisertib monotherapy in AML, and suggestion of synergy
in combination with chemotherapies, we performed a
phase I study to evaluate the safety and tolerability of alis-
ertib combined with conventional induction chemothera-
py for newly diagnosed AML. 
Methods
This study (clinicaltrials.gov Identifier:01779843) was
approved by the local institutional review board, and con-
ducted in accordance with the declaration of Helsinki.
Patients were eligible for enrollment if they were age 18 or
older with previously untreated AML based on WHO cri-
teria (≥ 20% bone marrow blasts).28 They were required to
have an Eastern Cooperative Oncology Group (ECOG)
performance status of 0-2, cardiac ejection fraction of
≥50%, and intact organ function including aspartate
aminotransferase (AST), alanine aminotransferase (ALT),
and alkaline phosphatase of <5 times the upper limit of
normal, direct bilirubin of <2.0 mg/dL, and creatinine
clearance of ≥40 mL/min. Standard cytogenetic and
molecular testing was performed at diagnosis. Those with
acute promyelocytic leukemia or with core-binding fac-
tors alterations, t(8;21) or inv(16)/t(16;16), were excluded.
Treatment
“7+3” induction chemotherapy included continuous
cytarabine infusion at 100 mg/m2 on days 1 through 7, and
idarubicin, dosed at 12 mg/m2 administered on days 1-3
by intravenous bolus. Starting on the day after the conclu-
sion of cytarabine infusion, alisertib was administered
orally according to dose level, twice daily (BID), for 7 days.
A bone marrow biopsy was performed at mid-induction
(between days 13 and 16). If bone marrow cellularity was
≥20% and myeloblast involvement was >5%, “5+2” rein-
duction, with continuous infusion of cytarabine at
100mg/m2 on days 1 to 5 and idarubicin 12 mg/m2 intra-
venously on days 1 and 2, was administered. If the bone
marrow cellularity was <20% but with >5% myeloblasts,
“5+2” reinduction was per clinician discretion. Patients
receiving reinduction did not receive additional doses of
alisertib during the remission induction period. A bone
marrow evaluation was performed at the time of periph-
eral hematologic recovery (absolute neutrophil count
(ANC) >1000/µL and platelet count >100,000/μL) or by
day 40 (range 35-42) or day 60 (if “5+2” was administered)
in the absence of optimal hematologic recovery.  A mar-
row biopsy was also performed on clinical suspicion of
resistant disease. Response criteria29 were categorized as
complete remission (CR), complete remission with incom-
plete platelet recovery (CRp), complete remission with
incomplete neutrophil recovery (CRi), or refractory dis-
ease.
Those achieving CR, CRi, or CRp, and eligible for allo-
geneic hematopoietic cell transplantation (HCT), could
come off study treatment during follow up for that pur-
pose; they were then followed for relapse and survival
outcomes. Otherwise, responding patients were eligible
for up to four cycles of consolidation therapy, at their clin-
ician's discretion. Consolidation therapy consisted of
cytarabine intravenously dosed at 3 gm/m2 every twelve
hours on days 1, 3, and 5 in patients < age 60, or 2 gm/m2
daily on days 1-5 in those ≥ age 60. Starting on day 6 of
each consolidation cycle, they received BID alisertib
according to dose level for 7 days. Once patients complet-
ed the cycles of consolidation and achieved count recov-
ery, they were eligible for alisertib maintenance. This was
administered BID according to the patient’s dose level on
days 1-7 of 21-day cycles, and continued until 12 months
after the start of induction, or until disease progression.
Patients were enrolled in one of three dose cohorts in a
“3+3” dose-escalation design. The three alisertib dose lev-
els were 10 mg, 20 mg, and 30 mg BID. Enrollment was
stopped at dose levels until all three patients in a cohort
were assessed for treatment-related dose-limiting toxici-
ties (DLTs). The DLT period was from initiation up to day
40, or day 60 if “5+2” was administered. If no DLTs were
experienced by the first three patients, three patients
were treated at the next dose level. If one DLT was expe-
rienced, an additional three patients were enrolled at the
same dose level. If fewer than 2 DLTs were experienced
among the six, dose escalation was permitted. If 2 or
more DLTs were experienced, the previous lower dose
was deemed the maximum tolerated dose (MTD).
Should DLTs not be encountered, the highest dose level
(30 mg BID) within the protocol would be the recom-
mended phase 2 dose (RP2D). Once the MTD or RP2D
was identified, an additional six patients were to be treat-
ed at that dose level.
Toxicities were graded according to Common
Terminology Criteria for Adverse Events (CTCAE version
4.0). Patients who experienced grade 3 or 4 non-hemato-
logic toxicity related to the study drug, and which persist-
ed for longer than 48 hours without resolution to ≤ grade
2, stopped alisertib. Grade 3 or 4 myelosuppression did
not lead to alisertib cessation. DLTs were defined as any
grade 4 or 5 non-hematologic toxicity, but excluding toxi-
cities such as infection related to neutropenia, grade 4
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fatigue or anorexia, and grade 4 nausea, vomiting, diar-
rhea, or electrolyte abnormalities which were reversible
with the appropriate therapies. Grade 3 non-hematologi-
cal toxicities that did not resolve to grade 2 by day 40 were
also considered DLTs, unless they were attributed to per-
sistent AML. Grade 4 neutropenia or thrombocytopenia at
day 40 following induction, or day 60 if “5+2” reinduction
was administered, were also considered DLTs, if the
cytopenias were not thought to be related to the underly-
ing leukemia.  
Correlative Methods
Culture of primary human AML cells
Cryopreserved primary bone marrow samples, collected
at baseline, were thawed and cultured for 36-48h on con-
fluent irradiated (2,000 rads) mouse MS5 stromal cells in
roswell park memorial institute (RPMI) medium supple-
mented with 20%  fetal bovine serum (FBS), 1% peni-
cillin/streptomycin, 50μM β-mercaptoethanol, and human
cytokines including  stem cell factor (SCF) (100ng/ml),
interleukin (IL)-3 (10ng/ml), IL-6 (20ng/ml), thrombopoi-
etin (TPO) (10ng/ml), and FLT3 ligand (FLT3L, 10ng/ml)
(Peprotech). Once cells were proliferative, each sample
was transferred to two new wells of irradiated stroma and
left untreated, or treated with 50nM alisertib for 18 hrs. 
Immunofluorescence Staining and Imaging
Patient leukemic cells were then spun at 1,000rpm for 3
minutes onto poly-lysine coated coverslips and fixed in
ice-cold methanol. Coverslips were blocked in tris-
buffered saline (TBS)/ bovine serum albumin (BSA),
stained for tubulin (dmlα: Sigma) and DNA (0.2 μg/mL
4′,6-diamidino-2-phenylindole (DAPI)), and mounted on
coverslips using ProLong Antifade mounting medium
(Molecular Probes). A Nikon Ti-E fluorescence microscope
equipped with a 60x objective and a Zyla sCMOS camera
was used to identify and capture images of mitotic cells in
each sample. The identification and characterization of
the mitotic spindle structure was performed on a mini-
mum of 20 mitotic figures per condition. 
Pharmacokinetics
Samples to determine the steady state minimum con-
centration of alisertib in plasma (Cmin
ss) were obtained
from each patient just prior to dosing on days 9, 11, and 14
during the first cycle. Peripheral blood (6mL) was drawn
into plastic tubes containing freeze-dried K2EDTA, mixed
by inversion, placed over ice until centrifuged (1,300 g, 10-
min, 4°C), whereupon the plasma was removed and
stored at -80ºC until assayed.  The concentration of alisert-
ib in human plasma was determined by reversed-phase
high performance liquid chromatography with tandem
mass spectrometric detection as previously reported, with
minor modifications.22 The analytical method was validat-
ed as recommended by current FDA Guidance for
Industry: Bioanalytical Method Validation, May 2001, to
document selectivity, carryover, accuracy, precision,
absolute recovery, and matrix effects. Alisertib was deter-
mined with an interday accuracy of 100.8% and a preci-
sion of 1.3% at the 5.0 ng/mL lower limit of quantitation.
Cmin
ss was calculated for each patient as the average of the
assayed concentration of alisertib in predose samples
obtained on days 11 and 14. The geometric mean and
standard deviation were calculated for Cmin
ss values for
patients evaluated at each dose level.  
Statistical Analysis
The primary study objective was to determine the type,
frequency, and severity of drug related toxicities and
define the MTD/RP2D. The study utilized a 3+3 design,
such that if the DLT rate exceeded 30% at a given level it
was less likely that the alisertib dose would be escalated.
The secondary objectives included assessment of the com-
plete response rate (CR/CRi/CRp), and the rates of overall
survival (OS) and progression-free survival (PFS) at one
year. 
OS was defined as the time from diagnosis to death and
censored at the last known date alive. PFS was defined as
the time from diagnosis to the first occurrence of progres-
sion or death and censored at the last known date alive
and disease-free. For the two patients who died before the
end of the DLT monitoring period, the date when they
were deemed off-treatment was used for survival esti-
mates. Survival was estimated for the trial and at the
RP2D (cohort 3 and dose expansion) with the Kaplan-
Meier method. The proportion of patients achieving a CR
or CRi was estimated along with a 90% exact binomial
confidence interval.
All grade 3 or higher toxicity was tabled regardless of
attribution and dose cohort. The date for either count
recovery or day 40 (D40), whichever was reported, were
used to determine when toxicities occurred. Grade 3 or
higher induction toxicities were tabled according to the
dose cohort. Additionally, for patients proceeding to con-
solidation therapy, post-induction toxicities were tabled.
Pharmacokinetic and correlative studies, as well as
patient and disease characteristics, including the number
of patients completing each stage of therapy (induction,
consolidation, and maintenance) were presented descrip-
tively.
Results
Patient Characteristics
Between May 2013 and January 2015, twenty-two
patients were enrolled on study. Baseline patient charac-
teristics are summarized in Table 1. The median age was
62.7 (range 41.7-75.1), and the majority were Caucasian
and male. Eight patients (36%) were aged ≥ 65 years.
Eight patients (36%) had secondary AML, six with preced-
ing MDS, one with a preceding myeloproliferative neo-
plasm, and one with therapy-related AML. The majority
of patients had intermediate-risk AML based upon cytoge-
netics (82%) or upon European LeukemiaNet (ELN) crite-
ria (73%). The most frequent additional mutations identi-
fied were NRAS (27%), IDH2 R140 (23%), NPM1 (18%),
IDH1 (14%), TP53 (14%), and FLT3-ITD (14%). 
Treatment and Toxicity Profile
A total of twenty-two patients were enrolled: three
patients (10mg BID), seven patients (20mg BID), six
patients (30mg BID), and an additional six at the deter-
mined RP2D of 30mg BID. All patients experienced at
least one expected grade 3/4 toxicity of anemia, leukope-
nia, thrombocytopenia, and febrile neutropenia. A single
DLT, prolonged grade 4 thrombocytopenia (beyond 40
days), thought to possibly be related to alisertib, occurred
at dose level two (20mg BID), prompting the enrollment of
six patients at that dose level. No additional DLTs were
observed. An expansion cohort of six patients was then
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added at 30mg BID. Two patient deaths occurred prior to
the DLT assessment period. The first mortality, at dose
level two, was caused by sepsis and thought to be unrelat-
ed to the study drug; this patient was replaced due to DLT
assessment ineligibility. The second mortality was due to
subarachnoid hemorrhage, again considered to be unrelat-
ed to the study drug; this patient was in the expansion
cohort, and no replacement was performed.
Alisertib was well tolerated. All grade 3 and higher non-
hematologic toxicities, regardless of attribution, are sum-
marized in Table 2.  In addition to the DLT noted above
and expected hematologic toxicities, other grade 4 toxici-
ties included respiratory failure (one patient, 5%) and sep-
sis (two patients, 9%), neither of which were thought to
be related to alisertib. The most frequent grade 3 toxicity
was rash (four patients, 18%), which were also not felt to
be related to alisertib. Non-hematologic toxicities possibly
or probably attributable to alisertib are provided in Table
3. The large majority were deemed < grade 3, apart from
two reversible episodes of grade 3 gastrointestinal toxicity.
Mucositis was the most frequent toxicity with a possible
relation to alisertib – this occurred in six patients (27%, all
< grade 3). The median time to partial peripheral count
recovery, as defined by an ANC of 500/mm3 and a platelet
count of 50,000/mm3, was 33 days (range 26-48 days). The
median time to full count recovery (defined as an ANC of
1000/mm3 and platelet count of 100,000/mm3) was 36
days (range 28-52 days).  
Efficacy
Treatment responses are summarized in Table 4, along
with chromosomal and molecular features available at
diagnosis for treated patients. Of the twenty-two
patients treated, only three (14%) had persistent disease
at mid-treatment, all of whom went on to receive “5+2”
reinduction therapy per protocol. A remission was
achieved in 86% (19/22; 90% CI 68-96%) of patients
(64% CR, 23% CRi). Of the remaining three patients,
two (9%) died during induction therapy and were
inevaluable for marrow response, and one (5%) had
refractory disease. The 12-month OS and PFS were 75%
(90% CI 55-87%) and 54% (34-71%), respectively. Seven
of the eight patients over age 65 years (87%) achieved a
complete remission (six CR, one CRi, one death). Ten
patients had high-risk AML, as defined as
secondary/therapy-related AML and/or displaying poor-
risk cytogenetic aberrations as per Medical Research
Council (MRC) and ELN criteria; the overall remission
rate for this group was 100% (80% CR, 20% CRi). 
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Table 1. Patient and disease characteristics.
Patient Characteristic                                                   N. (%)
N                                                                                                         22
Dose Level
10 mg BID                                                                                 3 (14)
20 mg BID                                                                                 7 (32)
30 mg BID                                                                                 6 (27)
Expansion                                                                                6 (27)
Age at Dx, median (range)                                              62.7 (41.7-75.1)
Sex
Male                                                                                          15 (68)
Female                                                                                      7 (32)
Race
Asian                                                                                           1 (4)
Black/African American                                                          1 (4)
Other                                                                                         3 (14)
White                                                                                        17 (77)
Ethnicity
Hispanic or Latino                                                                   0 (0)
Non-Hispanic                                                                         14 (64)
Ethnicity not known                                                               8 (36)
Disease Characteristics
Treatment-Related AML                                                            1 (4)
Underlying myeloid neoplasm†                                              7 (32)
Cytogenetic Risk
Poor-Risk                                                                                  4 (18)
Intermediate                                                                          18 (82)
Mutations*
FLT3**                                                                                      3 (14)
FLT3-ITD                                                                              3 (14)
FLT3-TKD                                                                             1 (4)
NPM1                                                                                         4 (18)
CEBPA                                                                                        2 (9)
IDH1                                                                                          3 (14)
IDH2                                                                                          6 (27)
NRAS                                                                                          6 (27)
KRAS                                                                                         3 (14)
TP53                                                                                           3 (14)
ELN Prognostic Groups
Favorable***                                                                           2 (9)
Intermediate-1                                                                        9 (41)
Intermediate-2                                                                        7 (32)
Adverse                                                                                     4 (18)
*Denominator out of all patients, some with unknown mutation status. †Six cases of
antecedent MDS, and one case of antecedent MPN. **One patient had concurrent
FLT3-ITD and FLT3-TKD mutations detected. ***One case of isolated NPM1 mutation,
and one case of isolated CEBPA mutation. Dx: diagnosis; AML: Acute myeloid
leukemia; ELN: European LeukemiaNet.
Table 2. Non-Hematologic Toxicities (grade 3 and higher) noted on
study.
Toxicity Description Grade 3 Grade 4 Grade 5
N. % N. % N. %
Colitis 2 9
Febrile neutropenia 18 82 1 5
Hypertension 1 5
Hyponatremia 1 5
Hypotension 1 5
Hypoxia 1 5
Infection 1 5
Intracranial hemorrhage 1 5
Lymph node pain 1 5
Nausea 1 5
Non-cardiac chest pain 1 5
Pneumonia 1 5
Rash (maculopapular) 4 18
Respiratory failure 1 5
Sepsis 1 5 2 9 1 5
Sinusitis 1 5
Skin infection 1 5
Tooth infection 1 5
Typhlitis 1 5
Ten patients (45%) received at least one cycle of cytara-
bine consolidation therapy on study; two patients (9%)
received four cycles of consolidation therapy. Two
patients were not able to proceed to consolidation, as per
the discretion of their treating physician, due to ongoing
infection.  Four patients (18%) received alisertib as main-
tenance therapy following consolidation. At the time of
manuscript preparation, six patients (27%) had experi-
enced disease relapse and six patients (27%) had died
(Figure 1). Among the four patients who received mainte-
nance alisertib therapy, one experienced relapse and there
were no instances of disease-related mortality. Ten
patients (45%) went on to receive allogeneic HSCT after
completing protocol-based therapy, four of whom
relapsed with two ultimately dying from the disease in the
protocol-determined follow-up period. 
A total of twelve patients were treated at the RP2D (six
from dose level three and six from the expansion cohort)
of which eleven (92%; 90% CI 66-99%) achieved a
CR/CRi. The median follow up for those remaining alive
was 13.5 months. Figure 2 displays the OS and PFS for
those treated at the RP2D. The 12-month OS for these
patients was 62% (90% CI 33-81%) and the 12-month
PFS was 42% (90% CI 17-65%).
Pharmacokinetics
The mean (±SD) Cmin
ss of alisertib was 229±89 nM,
552±317 nM and 652±304 nM for patients treated with
doses of 10 mg, 20 mg, and 30 mg BID, respectively. 
Mitotic Spindle Studies
For a subset of patients, baseline samples of leukemic
blasts were available for mitotic spindle study by
immunofluorescence staining (Patients #4, #17, #20 and
#22).  Following 18 hours of treatment with 50nM of alis-
ertib (a dose previously demonstrated to be optimal for
studies in culture), all of these samples exhibited response
(P<0.001). Treated samples demonstrated profound
defects in mitotic spindle assembly, manifested as increas-
es in mitotic cells exhibiting monopolar spindles and cor-
responding decreases in bipolar spindles (Figure 3), while
untreated mitotic cells exhibited primarily bipolar or mul-
tipolar spindles.
Discussion
The current therapeutic paradigm for AML is subopti-
mal for the majority of patients, and has remained
unchanged for decades. Outcomes are particularly poor
for certain higher risk subgroups, including older patients,
those with secondary disease, and those with poor-risk
cytogenetics.  Effective novel approaches to the treatment
of AML are necessary, and appear to be gradually emerg-
ing.  Recent data has suggested that AAK inhibition with
the targeted inhibitor alisertib may be an effective therapy
across a range of cancers,19-24,26 including advanced myeloid
malignancies.25 Others have found that the unique mitotic
toxicity of alisertib may synergize with cytotoxic
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Table 3. Non-hematologic toxicities on study by dose cohort, possibly or probably attributed to alisertib.
Cohort 1 (n=3) Cohort 2 (n=7) Cohort 3 (n=6) Expansion (n=6)
Toxicity Description Gr1 Gr2 Gr3 Gr4 Gr1 Gr2 Gr3 Gr4 Gr1 Gr2 Gr3 Gr4 Gr1 Gr2 Gr3 Gr4
Abdominal pain 1 1
Anorexia 2 1 1
Chills 1
Constipation 2 1 1
Diarrhea 1 1 1 1
Dizziness 1 1
Dysgeusia 1 1
Dyspepsia 1
Dyspnea 1
Edema limbs 1
Elevated alk phos 1 4 2
Fatigue 4 1 1
Headache 1 1
Hyperbilirubinemia 1 1
Hyperglycemia 1
Hypertension 1
Hypocalcemia 1
Oral mucositis 2 2 1 1
Nausea 3 1
Skin changes / Rash 1
Transaminitis 2 3 2 2
alk phos: alkaline phosphatese; Gr: grade.
chemotherapy to enhance efficacy.15-18 Herein we report
the results of a phase I study of alisertib combined with
conventional induction chemotherapy for newly diag-
nosed AML.  
The addition of alisertib to induction was well-tolerated
without significant toxicity.  Although limited by size in
this phase I study, our data also suggests that the combi-
nation was promising, with higher response rates than
those which have been historically reported.2,9,30,31 The
composite rate of remission (CR and CRi) across all
A.T. Fathi et al.
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Table 4. Course and outcome, by dose cohort, for patients on trial. Nineteen of twenty-two patients (86%) achieved a CR or CRi.
Case Cohort Sex Age Karyotype Detected Mutations Reinduction Response Consolidation Stem cell Status at
(5+2) transplant 12-months
1 1 M 58 t(3;12;21) - N CR N Y Alive
2 1 F 51 t(2;3) FLT3-ITD N CR Y Y Alive
3 1 M 75 isochromosome (17q); - N CRi N N Alive†
monosomy 17p
4 2 M 62 monosomy 7; trisomy 8 CEBPA, IDH2, NRAS N CRi N N Dead
5 2 M 70 normal IDH2 N CR Y N Alive
6 2 F 43 normal FLT3-ITD, FLT3-TKD, NPM1, NRAS N CR Y N Alive
7 2 M 48 normal NRAS, KRAS N Refractory N N Alive
8 2 F 74 normal FLT3-ITD, NPM1 N CR N N Alive
9 2 M 71 normal CEBPA, IDH1 N - - - Dead
10 2 M 61 trisomy 8 IDH2 N CR Y N Alive
11 3 M 69 trisomy 9; del(20q) JAK2 N CR Y Y Alive
12 3 M 61 isochromosome (22q) - N CRi Y Y Alive
13 3 F 61 complex TP53 N CR Y N Dead
14 3 F 68 normal IDH2 N CR Y Y Alive
15 3 M 69 del (Y) NPM1, NRAS, APC N CR N Y Alive
16 3 M 63 normal IDH1, IDH2, CDH1, SMAD4 N CR Y Y Alive
17 Exp M 42 complex TP53, NRAS, KRAS N CR N Y Dead
18 Exp F 43 normal IDH1 Y - - - Dead
19 Exp M 64 normal - N CRi N N Alive
20 Exp F 59 normal NPM1 N CR Y N Alive*
21 Exp M 64 normal IDH2 Y CRi N Y Alive
22 Exp M 67 complex TP53, NRAS, KRAS Y CR N Y Dead
*Remains on study. †Lost to follow up. Patients 9 and 18 died prior to response assessment. Exp: Expansion; CR: complete remission; CRi: remission with incomplete neutrophil recovery.
Figure 1. Summary plot of patient clinical
course, sorted by follow up and treatment arm.
CR: complete remission; CRi:  remission with
incomplete neutrophil recovery.
patients was 86%, and among those evaluable for
response assessment, all but one achieved remission.
More than one third of patients on study had high-risk
AML, as established by karyotype or antecedent marrow
process, and all of these patients achieved remission.  All
seven evaluable patients over age 65 also achieved remis-
sion.  Mid-treatment bone marrow biopsies were per-
formed according to the established approach for “7+3”
induction, and only three of the twenty-two patients on
study (14%) required reinduction for residual disease, a
rate much lower than that previously reported with con-
ventional induction.1,2,31 Among the high-risk patients
studied, three patients had mutations impacting TP53, all
with concurrent complex karyotypes. All achieved com-
plete remission on study, and two went on to have stem
cell transplantation.  Nevertheless, none of the three were
alive at 12 months, which is, unfortunately, consistent
with the grim prognosis associated with the TP53 alter-
ation.32-35 
The pharmacokinetics of oral alisertib monotherapy has
been characterized in phase I clinical trials.22,23 The drug
has an apparent biological half-life of 19-23 hours, and
steady-state pharmacokinetics is achieved within 7 days
of repeated daily or twice daily dosing.  The mean Cmin
ss
exhibited a relatively high degree of variability without a
clear dose-dependent difference or even a reversal in mag-
nitude between successive dose levels in some cases.
Comparative data for the same dose levels evaluated in
the present investigation have not previously been report-
ed for the twice daily dosing schedule.  Approximate val-
ues of the mean Cmin
ss for the 50 mg BID were reported as
1,000 nM and 2,400 nM in the two single agent phase I
studies. The Cmin
ss of alisertib achieved with doses of 10,
20, and 30 mg BID in AML patients following the "7+3"
remission induction regimen was in good general agree-
ment with the expected drug levels based upon these prior
early phase studies. 
Aurora kinases are essential regulators of chromosomal
alignment and separation during mitosis.  Each of the
enzymes, aurora A, B and C kinases, have key and coordi-
nated functions in the mitotic process,36-38 including centro-
some maturation, spindle assembly, chromosomal separa-
tion, and mitotic checkpoint regulation.36,39-42 AAK amplifi-
cation has been detected across a range of malignancies,
although its role in malignant transformation remains
unclear.43-45 Overexpression of AAK may be insufficient,
and some studies have suggested that additional concur-
rent activating mutations, in genes such as RAS, may be
necessary to transform cells.46 A key contribution appears
to be the role of AAK in chromosomal segregation, with
overexpression leading to errors in this process.
Aneuploidy, aberrant spindle formation, abortive mitoses,
and other defects promote genetic instability and likely
contribute to oncogenic transformation.38,43,47,48 In addition,
an effect on tumor suppressor function may be important.
AAK directly phosphorylates TP53, and amplification of
the former may cause degradation of the latter.49-51
Nevertheless, given the broad impact on cell cycling and
survival, the efficacy of AAK inhibitors in malignancy may
be more generally related to anti-mitotic effects rather
than to suppressing addiction to AAK activity.38
As a selective inhibitor of AAK, alisertib triggers the
development of chromosomal defects and aneuploidy,
with resulting cellular senescence and apoptosis in malig-
nant cell lines.13,15 In multiple phase I and phase II clinical
studies across solid tumor and hematologic malignan-
cies,19-26 alisertib demonstrated a broad range of efficacy. In
myeloid malignancies, a single-arm phase II study evaluat-
ed the efficacy of alisertib monotherapy in fifty-seven
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Figure 2. Overall (OS) and progression-free survival (PFS) estimates for those
treated in cohort 3 and the expansion cohort. OS is noted in the solid black line,
while PFS is the red dashed line.
Figure 3. Spindle defects following
alisertib treatment of baseline pri-
mary AML samples. Proliferative
patient samples were left untreated,
or treated with 50nM alisertib, and
assessed for defects in mitotic spin-
dle formation. The percentage of
mitotic primary cells demonstrating
defective monopolar spindle struc-
tures from untreated patient sam-
ples (blue bars) and those treated
with alisertib (red bars) are demon-
strated. All samples displayed an
increase in monopolar spindle for-
mation during mitosis following alis-
ertib treatment. Representative
images of bipolar and monopolar
mitotic spindles in AML samples are
shown in the panel on the right.
patients with advanced AML and high-grade MDS.25
Alisertib was administered at 50 mg twice daily for 7 con-
secutive days in 21-day cycles. The majority of patients
had received prior therapies and had relapsed or refractory
disease. Alisertib was well-tolerated, with the predomi-
nant grade 3/4 adverse events being febrile neutropenia,
thrombocytopenia, anemia, and fatigue. Six responses
were observed, all in AML patients, with five patients
experiencing a partial remission, and one patient experi-
encing a prolonged CR lasting longer than a year.  49% of
patients were also reported to have achieved stable dis-
ease.25
These findings suggested clinical activity with alisertib,
now further supported by our data. Of twenty patients
evaluable for response assessment, nineteen achieved
remission. Only three of the twenty-two enrolled patients
had persistent disease at mid-treatment with "7+3". We
also investigated available baseline samples from patients
on study. In this small subgroup of four patients, spindle
formation was clearly impacted by alisertib, with a
marked increase in aberrant monopolar spindle formation.
Intriguingly, all four of these patients went on to achieve
remission on study, despite three of the four having high-
risk karyotypic abnormalities and/or MDS-derived sec-
ondary AML. Additional study of primary samples from
AML patients is necessary in order to establish trends, and
these are currently ongoing.
The addition of alisertib was well-tolerated. Common
toxicities on study were neutropenic fever, thrombocy-
topenia, and anemia (all expected with induction
chemotherapy), and less common toxicities were rash and
oral mucositis.  Combining cytotoxic agents with induc-
tion chemotherapy raises concern for prolonged cytope-
nias; only one DLT, a case of prolonged thrombocytopenia,
was noted on the study. Patients are frequently discharged
following a degree of hematologic recovery rendering
them clinically safe outside of the hospital, which at our
institution typically includes an ANC of 500/mm3 and
platelet transfusion independence. Encouragingly, among
our patients, the median time to such a threshold was not
greatly impacted, at 33 days.  Nevertheless, we do
acknowledge that there was a mild prolongation of time to
peripheral count recovery, when compared to the approxi-
mate hospitalization duration expected for standard induc-
tion. However, this modest prolongation among our popu-
lation did not contribute to morbidity or mortality in this
study. The two deaths seen during induction, though relat-
ed to cytopenias, occurred prior to day 30.
Our study was limited by its small size, being a phase I
study with the key aim of determining tolerability and an
MTD/RP2D. It was also limited by the relative hetero-
geneity of its population, with a mixture of high- and
intermediate-risk AML cases. The mutational profile of
patients in this small phase I study may also not fully
reflect the larger population of AML patients.
Additionally, a sizeable proportion of our patients went on
to consolidative stem cell transplantation, and did not
receive ongoing therapy on study. These trends are impor-
tant since they can impact the interpretation of efficacy
endpoints, a consideration which reinforces the need for
further clinical study.  Despite this, the overall outcomes
for our cohort are favorable relative to historical out-
comes, particularly given their age (median 63 years) and
disease risk (36% with secondary AML and 18% with
poor-risk cytogenetics). We demonstrated that alisertib
combined with induction chemotherapy is safe and well-
tolerated, and established an RP2D of 30mg BID in this
setting. We also found that alisertib is safe among higher
risk patients, with a promising suggestion of efficacy.  All
patients with high-risk AML (as defined by karyotype or
antecedent marrow process), and all evaluable patients
above age 65 achieved remission on study. Based on this
promising data, we are currently conducting a phase II
study of alisertib combined with “7+3” induction
chemotherapy, specifically for newly diagnosed patients
with higher risk AML (clinicaltrials.gov Identifier:02560025).  
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